Assembly Biosciences (ASMB) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Assembly Biosciences

NasdaqGS•Healthcare•Biotechnology

$25.48-0.63(-0.02%)After hours

Market Cap

$492.27M

P/S

6.6x

P/B

1.6x

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

How this company scores

AverageMetricSide Score: 59/100

Strongest: Growth (20/25); weakest: Cash & Earnings Quality (11/25).

Profitability13/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality11/25

Strengths

Growing revenueInterest easily coveredCash-backed earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 6.6x5y range 2.2x – 141.7x

Currently near its 15-quarter median.

P/B · 1.6x5y range 1.6x – 23.1x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $492.27M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $74.84M
Q. Revenue: $13.37M
TTM EBITDA: $-8.62M
TTM Op. Income: $-8.80M
Q. Op. Income: $-6.34M
TTM Net Income: $-42,000
Q. Net Income: $-3.86M
EPS: $-0.2
Shares Out.: $18.85M

$74.84M in TTM revenue grew 125.1% YoY, reaching $13.37M last quarter. TTM EBITDA of $-8.62M and TTM operating income of $-8.80M show growth is flowing through to the bottom line. However, net income is negative at $42,000 — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 125% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -47.3%
Op. Margin: -47.4%
Net Margin: -28.8%

Op. margin of -47.4% is up 67.8% YoY — cost efficiency is improving. Net margin at -28.8% Over the past year, operating margin is up 59% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.6x
P/B Ratio: 1.6x

P/S of 6.6x and P/B of 1.6x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $330.83M
Cash: $32.29M
Long-Term Debt: N/A
Book Value: $305.65M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-15.49M
TTM Free Cash Flow: $-38.57M
FCF Margin: -51.5%
FCF / Net Income: 918.2

TTM FCF of $-38.57M on $-15.49M in operating cash flow. The FCF / Net Income ratio of 918.2x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.